Table 2.

Summary of culture conditions using human cells as a starting source

	Feeder cells	Supplements		Media	Duration	Functional SP?	Reference
0P9-DL
UCB-HSPC	OP9-DL	IL-7	FIt3L	α-MEM + 20% FBS	9–10 Weeks	Yes	Awong [17]
ESC	OP9 0P9-DL	Ascorbic acid MTG transferrin BMP4 bFGF Activin A SB VEGF	Dkk	Stem Pro 34	4 weeks	Yes	Kennedy [46]
			IL-6
			IGF-1
			IL-11
			SCF
			EPO
			TPO
			IL-3
			Flt3L
iPSC	0P9 OP9-DL	Ascorbic acid MTG transferrin BMP4 bFGF Activin A SB VEGF	Dkk	Stem Pro 34	4 weeks	No	Kennedy [46]
			IL-6
			IRF-1
			IL-11
			SCF
			EPO
			TPO
			IL-3
			Flt3L
FTSC
BM-HSPC	Fetal thymic stromal cells	IL-2 IL-7 IL-12	Flt3L SCF	IMDM + 20% FBS	5 weeks	Yes	Freedman [23]
pFib-DL
UCB-HSPC	Primary fibroblast-DL	IL-7 SCF	FIt3L	α-MEM1 20% FBS	5 weeks	Yes	Mohtashami [25]
pFib
UCB-HSPC primary fibroblast	Keratinocytes	IL-7 IL-15	FIt3L	DMEM + 10% FBS	3–4 weeks	No	LaPenna [29]
DII-Fc
UCB-HSPC	-	IL-7 SCF TPO	Flt3L ascoribic acid	α-MEM + 20% FBS	3–4 weeks	No	Huijskens [35]

Abbreviations: bFGF, basic fibroblast growth factor; BM-HSPC, bone marrow-derived hematopoietic stem progenitor cells; BMP, bone morphogenic protein; Dkk, Dickkopf protein; DL/Dll, delta-like ligand; DMEM, Dulbecco’s modified Eagle’s medium; EPO, erythropoietin; ESC, embryonic stem cell; FBS, fetal bovine serum; Flt3L, FMS-like tyrosine kinase 3 ligand; FTSC, fetal thymic stromal cells; IGF, insulin-like growth factor; IL, interleukin; IMDM, Iscove’s Modified Dulbecco’s Medium; iPSC, induced pluripotent stem cell; α-MEM, minimum essential medium α; MTG, monothioglycerol; pFib, primary fibroblast; RPMI, Roswell Park Memorial Institute medium; SB, SB-431542; SCF, stem cell factor; SP, single positive; TPO, thrombopoietin; UCB-HSPC, umbilical cord blood-derived hematopoietic stem progenitor cells; VEGF, vascular endothelial growth factor.